{
    "root": "357ee4ea-1ab9-50e4-e063-6294a90afda2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levetiracetam",
    "value": "20250519",
    "ingredients": [
        {
            "name": "MALTITOL",
            "code": "D65DG142WK"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "ACESULFAME POTASSIUM",
            "code": "23OV73Q5G9"
        },
        {
            "name": "AMMONIUM GLYCYRRHIZATE",
            "code": "3VRD35U26C"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "LEVETIRACETAM",
            "code": "44YRR34555"
        }
    ],
    "indications": "levetiracetam oral solution indicated treatment partial-onset seizures patients 1 month age older ( 1.1 ) levetiracetam oral solution indicated adjunctive therapy treatment : myoclonic seizures patients 12 years age older juvenile myoclonic epilepsy ( 1.2 ) primary generalized tonic-clonic seizures patients 6 years age older idiopathic generalized epilepsy ( 1.3 )",
    "contraindications": "oral solution pediatric patients body weight ≤ 20 kg ( 2.1 ) pediatric patients , weight-based dosing oral solution calibrated measuring device ( household teaspoon tablespoon ) ( 2.1 ) partial-onset seizures ( monotherapy adjunctive therapy ) 1 month < 6 months : 7 mg/kg twice daily ; increase 7 mg/kg twice daily every 2 weeks recommended dose 21 mg/kg twice daily ( 2.2 ) 6 months < 4 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 25 mg/kg twice daily ( 2.2 ) 4 years < 16 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.2 ) adults 16 years older : 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.2 ) myoclonic seizures adults pediatric patients 12 years older 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.3 ) primary generalized tonic-clonic seizures 6 years < 16 years : 10 mg/kg twice daily , increase increments 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.4 ) adults 16 years older : 500 mg twice daily , increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.4 ) adult patients impaired renal function dose adjustment recommended , based patient ’ estimated creatinine clearance ( 2.5 , 8.6 )",
    "warningsAndPrecautions": "levetiracetam oral solution usp , 100 mg/ml clear , colorless grape flavored liquid ndc : 70518-3803-00 ndc : 70518-3803-01 ndc : 70518-3803-02 ndc : 70518-3803-03 ndc : 70518-3803-04 ndc : 70518-3803-05 ndc : 70518-3803-06 ndc : 70518-3803-07 ndc : 70518-3803-08 ndc : 70518-3803-09 packaging : 10 1 box packaging : 7.50 ml 1 cup , unit dose packaging : 10 1 box packaging : 5 ml 1 cup , unit dose packaging : 10 1 box packaging : 12.50 ml 1 cup , unit dose packaging : 10 1 box packaging : 20 ml 1 cup , unit dose packaging : 10 1 box packaging : 15 ml 1 cup , unit dose store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . dispense tight , light-resistant container child-resistant closure . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "levetiracetam contraindicated patients hypersensitivity levetiracetam . included anaphylaxis angioedema [ ( 5.4 ) ] .",
    "indications_original": "Levetiracetam oral solution is indicated for the treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) Levetiracetam oral solution is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3)",
    "contraindications_original": "Use the oral solution for pediatric patients with body weight ≤ 20 kg (2.1) For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) (2.1) Partial-Onset Seizures (monotherapy or adjunctive therapy) 1 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily (2.2) 6 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily (2.2) 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.2) Adults 16 Years and Older:  500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily (2.2) Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.3) Primary Generalized Tonic-Clonic Seizures 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.4) Adults 16 Years and Older:  500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.4) Adult Patients with Impaired Renal Function Dose adjustment is recommended, based on the patient’s estimated creatinine clearance (2.5 , 8.6)",
    "warningsAndPrecautions_original": "Levetiracetam Oral Solution USP, 100 mg/mL is a clear, colorless grape flavored liquid\n                  \n                  NDC: 70518-3803-00\n                  NDC: 70518-3803-01\n                  NDC: 70518-3803-02\n                  NDC: 70518-3803-03\n                  NDC: 70518-3803-04\n                  NDC: 70518-3803-05\n                  NDC: 70518-3803-06\n                  NDC: 70518-3803-07\n                  NDC: 70518-3803-08\n                  NDC: 70518-3803-09\n                  PACKAGING: 10 in 1 BOX\n                  PACKAGING: 7.50 mL in 1 CUP, UNIT DOSE\n                  PACKAGING: 10 in 1 BOX\n                  PACKAGING: 5 mL in 1 CUP, UNIT DOSE\n                  PACKAGING: 10 in 1 BOX\n                  PACKAGING: 12.50 mL in 1 CUP, UNIT DOSE\n                  PACKAGING: 10 in 1 BOX\n                  PACKAGING: 20 mL in 1 CUP, UNIT DOSE\n                  PACKAGING: 10 in 1 BOX\n                  PACKAGING: 15 mL in 1 CUP, UNIT DOSE\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Dispense in a tight, light-resistant container with a child-resistant closure.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Levetiracetam is contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema\n \n  [see\n  \n   Warnings and Precautions (5.4)]\n \n  ."
}